Amnestic Transitional Cognitive Decline in Aging and Preclinical Alzheimer’s Disease
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
INTRODUCTION
This study proposes objective, standardized criteria for defining amnestic transitional cognitive decline (aTCD) in aging and preclinical Alzheimer’s disease (AD), supported by a comprehensive multimodal biomarker characterization.
METHODS
This prospective observational study analyzed 3-year longitudinal data from the Alzheimer’s and Families+ cohort, including 350 cognitively unimpaired participants. The presence of aTCD was defined using robust longitudinal neuropsychological references with a multivariate base rate threshold of significant cognitive decline; its association with fluid (plasma and CSF) and neuroimaging biomarkers (PET and MRI) was evaluated using mixed-effects and voxel-wise regression models, respectively.
RESULTS
Applying the defined criteria, aTCD was identified in 35 individuals (10%), demonstrating significant associations with Core AD biomarkers (Aβ and tau) and biomarkers of non-specific processes involved in AD pathophysiology (neurodegeneration and inflammation).
DISCUSSION
These findings underscore the need for standardized clinical staging criteria to improve early detection and risk stratification in aging and preclinical AD.
